Icosavax, Inc. Intellectual Property Contracts & Agreements
8 Contracts & Agreements
- License Agreements (8 contracts)
- Amendment No. 3 to Exclusive Patent License Agreement, dated May 24, 2023, between the Registrant and National Institute of Allergy and Infectious Diseases (Filed With SEC on August 14, 2023)
- Amended and Restated Exclusive License Agreement, dated June 8, 2023, between the Registrant and the University of Washington (Filed With SEC on August 14, 2023)
- Amendment No. 3 to Exclusive License Agreement, effective as of June 3, 2022, between University of Washington and the Registrant (Filed With SEC on August 15, 2022)
- Non-Exclusive License Agreement, dated September 16, 2021, by and between the University of Washington and the Registrant (Filed With SEC on March 30, 2022)
- Patent License Agreement, dated June 2, 2021, between the Registrant and the University of Texas at Austin (Filed With SEC on July 7, 2021)
- Non-Exclusive Patent License Agreement, dated June 28, 2018, between the Registrant and National Institute of Allergy and Infectious Diseases, as amended (Filed With SEC on July 7, 2021)
- License and Exclusive Option Agreement, dated July 2, 2020, between the Registrant and University of Washington, as amended (Filed With SEC on July 7, 2021)
- Exclusive License Agreement, dated June 29, 2018, between the Registrant and University of Washington, as amended (Filed With SEC on July 7, 2021)
